Novartis sees external route as best for CV asset

Private investment platform Blackstone Life Sciences and Novartis (NOVN: VX) have launched Anthos Therapeutics, a biopharma focused on cardiovascular (CV) disease.

As part of this launch, the Swiss pharma giant has licensed to Anthos MAA868 an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway.

"This is part of our strategy to work with innovators outside our walls to advance medicines"A promising anti-thrombotic modulating genetically and pharmacologically validated components of the intrinsic pathway, MAA868 is seen as having the potential to prevent a variety of CV disorders with minimal or no bleeding risk within a new long-acting treatment paradigm, which would provide major advantages over conventional standards of care.